Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
暂无分享,去创建一个
C. Rudin | S. Peters | A. Navarro | M. Pietanza | J. Mazières | J. Yang | M. Gumus | G. Kalemkerian | H. Kim | D. Rodríguez-Abreu | M. Gottfried | M. Awad | Yi Luo | T. Csoszi | T. Kato | P. Cheema | M. Wollner | M. Gümüş | F. Orlandi | A. Luft | V. Ebiana | T. Csőszi | Keynote Investigators | H. R. Kim
[1] R. Hubbard,et al. A systematic review of survival following anti-cancer treatment for small cell lung cancer. , 2020, Lung cancer.
[2] D. Planchard,et al. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] Young Hak Kim,et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial , 2019, The Lancet.
[4] A. Italiano,et al. Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158 , 2019, Annals of Oncology.
[5] C. Rudin,et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.
[6] J. Lunceford,et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Hellmann,et al. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] A. Tafreshi,et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[9] A. Mansfield,et al. First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[10] J. Lunceford,et al. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. , 2018, Archives of pathology & laboratory medicine.
[11] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[12] A. Farago,et al. Current standards for clinical management of small cell lung cancer. , 2018, Translational lung cancer research.
[13] D. Morgensztern,et al. Treatment advances in small cell lung cancer (SCLC) , 2017, Pharmacology & therapeutics.
[14] J. Li,et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages , 2017, Scientific Reports.
[15] C. Rudin,et al. Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails". , 2016, JAMA oncology.
[16] C. Rudin,et al. Small cell and neuroendocrine tumors of the lung , 2015 .
[17] Yoshiaki Uyama,et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Frank Bretz,et al. Multiple Testing in Group Sequential Trials Using Graphical Approaches , 2013 .
[19] R. Herbst,et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. , 2012, Clinical lung cancer.
[20] Edward L Spitznagel,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.